Long title
A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant
Date receipt dossier
EudraCT number
2021-001379-18
Company / Sponsor
Quell Therapeutics Limited
Phase
I/II
Treated organism
Humans
Indication category
Infectious disease
Disease
Anti-graft rejection treatment
Therapeutic approach
Anti-graft rejection treatment
Genetic modification
BCMA CAR; shRNA CD3ζ; tCD34
Method of transfer of nucleic acid of interest
Moloney murine leukemia virus
Administered biological material
Autologous T-cells retrovirally transduced with BCMA-CAR, ShRNA CD3ζ and tCD34
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, Cliniques Universitaires Saint-Luc, Institut Jules Bordet
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
QEL-001